di Martino V, Lunel F, Cadranel J F, Hoang C, Parlier Y, Le Charpentier Y, Opolon P
Service d'Hépato-Gastroentérologie, Groupe hospitalier Pitie-Salpetriere, Paris, France.
J Viral Hepat. 1996 Sep;3(5):253-60. doi: 10.1111/j.1365-2893.1996.tb00051.x.
Chronic hepatitis B viral infection is common in human immunodeficiency virus (HIV) carriers, but the effectiveness of interferon therapy is still unknown. We report the results of a long-term pilot study of five patients, who were infected with HIV and chronic hepatitis B, treated by interferon. Five males co-infected with HIV and hepatitis B virus (HBV) (mean age 27 years) were given a 6-month course of interferon (IFN)-alpha 2b 5 million units (MU) three times weekly. On initiating the treatment, their CD4 lymphocyte count was 340-553 mm-3, their CDC stage was IIa-III; all had histologically proven chronic hepatitis, with Knodell's score ranging from 6-10, and active HBV replication (HBV DNA and hepatitis B e antigen (HBeAg) were detectable). There was no associated hepatitis delta virus (H delta V) or hepatitis C virus (HCV) infection. Follow-up was for 53 months on average (24-74 months). After the treatment, hepatitis B e antibody (HBeAb) and hepatitis B s antibody (HBsAb) seroconversion was observed in one patient, HBeAb seroconversion alone in two patients, HBV DNA was absent from serum in three patients, and HBV DNA significantly decreased in one patient. The serum alanine aminotransferase (ALT) activity was normal in four patients. Histological improvement was obtained in four patients. The HIV stage remained unchanged in all patients during the whole follow-up. These preliminary results suggest that interferon can be successfully used in immunocompetent HIV carriers with chronic hepatitis B as well as in HIV-negative patients.
慢性乙型肝炎病毒感染在人类免疫缺陷病毒（HIV）携带者中很常见，但干扰素治疗的有效性仍不清楚。我们报告了一项对五名感染HIV和慢性乙型肝炎的患者进行长期试点研究的结果，这些患者接受了干扰素治疗。五名同时感染HIV和乙型肝炎病毒（HBV）的男性（平均年龄27岁）接受了为期6个月的干扰素（IFN）-α2b治疗，每周三次，每次500万单位（MU）。开始治疗时，他们的CD4淋巴细胞计数为340 - 553/mm³，疾病控制中心（CDC）分期为IIa - III期；所有患者均经组织学证实为慢性肝炎，Knodell评分在6 - 10之间，且有活跃的HBV复制（可检测到HBV DNA和乙型肝炎e抗原（HBeAg））。无相关的丁型肝炎病毒（H delta V）或丙型肝炎病毒（HCV）感染。平均随访53个月（24 - 74个月）。治疗后，一名患者观察到乙型肝炎e抗体（HBeAb）和乙型肝炎表面抗体（HBsAb）血清学转换，两名患者仅出现HBeAb血清学转换，三名患者血清中未检测到HBV DNA，一名患者的HBV DNA显著下降。四名患者的血清丙氨酸氨基转移酶（ALT）活性正常。四名患者获得了组织学改善。在整个随访期间，所有患者的HIV分期均保持不变。这些初步结果表明，干扰素可成功用于免疫功能正常的慢性乙型肝炎HIV携带者以及HIV阴性患者。
